Long-term impact of a birch/alder/hazel or birch-only liquid sublingual immunotherapy on birch-family pollen respiratory allergy: A real-world study
Allergology International · 2025
DOI: 10.1016/j.alit.2025.02.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergology International, 2025. Verfasst von Stefan Zielen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Research Centre, Medaimun GmbH, Frankfurt am Main, Germany; Department of Paediatrics, University Hospital Frankfurt, Goethe-University, …. Hauptthemen laut MEDLINE: Sublingual Immunotherapy, Betula, Pollen, Rhinitis, Allergic, Seasonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ashikaga Institute of Technology.
Abstract (Originalsprache)
BACKGROUND: Patients with allergic rhinitis (AR) and/or mild or moderate asthma derived from birch-family pollen allergy can be treated with liquid sublingual immunotherapy (SLIT-liquid). This study evaluated the impact of two SLIT extracts on AR and asthma progression or onset in these patients. METHODS: This was a sub-analysis of a retrospective, longitudinal comparative cohort study that used a German prescription database. Patients treated with 3-tree (birch/alder/hazel) or birch-only SLIT-liquid and followed up for up to 6 years after treatment were compared with controls dispensed symptomatic medications. Multiple regression analysis compared dispensation data as a proxy for disease status and progression. RESULTS: A total of 493 patients treated with 3-tree SLIT-liquid and 311 treated with birch SLIT-liquid were analysed vs. 44,835 patients included as controls. Overall, 70.5 % of patients presented solely AR, 24.2 % solely asthma, and 5.3 % both diseases. Compared with controls, patients treated with 3-tree SLIT-liquid had reduced risk of AR [odds ratio (OR) = 3.21, 95 % CI 2.54-4.06, p < 0.001], asthma progression (OR = 2.03, 95 % CI 1.43-2.89, p < 0.0001), or asthma onset (OR = 0.592, 95 % CI, 0.408-0.860, p = 0.006). Birch-only SLIT-liquid showed similar effectiveness in reducing AR and asthma medication dispensation but no significant effect in reducing new-onset asthma. CONCLUSIONS: This real-world study demonstrated the effectiveness of treatment with 3-tree SLIT-liquid or birch SLIT-liquid in slowing the progression of birch-family pollen allergy. 3-tree SLIT-liquid covering a broader repertoire of epitopes mimicking natural exposure throughout the year may be valuable for patients sensitised to birch and/or alder and/or hazel pollen suffering from overlapping tree-pollen seasons.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Respiratory Research Centre, Medaimun GmbH, Frankfurt am Main, Germany; Department of Paediatrics, University Hospital Frankfurt, Goethe-University, Frankfurt am Main, Germany. Electronic address: s.zielen@medaimun.de.
- Epidemiology, IQVIA, Frankfurt am Main, Germany.
- Competence Centre for Allergology and Immunology, Karl Landsteiner University, Krems, Austria.
- Paediatric and Adolescent Medicine, University Hospital Augsburg, Augsburg, Germany.
- Stallergenes Greer, Antony, France.
- Respiratory Pharmacology Research Unit, VIM Suresnes, UMR_0892, University Paris-Saclay, Suresnes, France; Department of Airway Diseases, Hospital Foch, Suresnes, France.
Förderung
- Ashikaga Institute of Technology
Zitieren
APA
Zielen, S., Richter, H., Zieglmayer, P., Gerstlauer, M., Cognet-Sicé, J., Scurati, S., & Devillier, P. (2025). Long-term impact of a birch/alder/hazel or birch-only liquid sublingual immunotherapy on birch-family pollen respiratory allergy: A real-world study. Allergology International. https://doi.org/10.1016/j.alit.2025.02.002
Vancouver
Zielen S, Richter H, Zieglmayer P, Gerstlauer M, Cognet-Sicé J, Scurati S, et al. Long-term impact of a birch/alder/hazel or birch-only liquid sublingual immunotherapy on birch-family pollen respiratory allergy: A real-world study. Allergology International. 2025. doi:10.1016/j.alit.2025.02.002
BibTeX
@article{Zielen2025,
author = {Zielen, Stefan and Richter, Hartmut and Zieglmayer, Petra and Gerstlauer, Michael and Cognet-Sicé, Josiane and Scurati, Silvia and Devillier, Philippe},
title = {Long-term impact of a birch/alder/hazel or birch-only liquid sublingual immunotherapy on birch-family pollen respiratory allergy: A real-world study},
journal = {Allergology International},
year = {2025},
doi = {10.1016/j.alit.2025.02.002}
}
EUVIMED